CClinicalTrials.gg
CompletedNCT03302273Updated Apr 21, 2022

Corneal Epithelial Stem Cells and Dry Eye Disease

An interventional study of Corneal Epithelial Stem Cell Transplant in Dry Eye Syndromes, Dry Eye and Ocular Inflammation, sponsored by Sloan W. Rush, MD. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-04-21.

Sponsored by Sloan W. Rush, MD · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

To study of a novel, therapeutic Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) in the treatment of severe dry eye disease that is failing conventional treatments. This pilot study will carefully observe and monitor each qualifying and willing individual for response to treatment, signs of toxicity and adverse effects from the treatment, and for ability of the treatment to improve comfort and restore vision.

Read the detailed description

Eligible patients presenting with severe dry eye disease that have failed treatment with conventional measures will be screened for inclusion into the study. The treatment will consist of administration of formulated topical eye drops containing cadaveric epithelial stem cell-derived product. These eye drops will be transplanted by topical self-administration by the patient four times daily in both eyes for a three month interval.

02

Conditions studied

  • Dry Eye Syndromes
  • Dry Eye
  • Ocular Inflammation
  • Ocular Surface Disease
  • Ocular Discomfort
  • Blepharitis

Keywords

  • stem cell therapy
  • dry eye disease
03

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinical diagnosis of advanced dry eye disease
  • Severe dry eye symptoms despite having tried over a half dozen treatments

Exclusion criteria

Exclusion Criteria:

  • Not willing to undergo clinical trial
  • Unable to comply with treatment regimen
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Corneal Epithelial Stem Cell Transplant

    The treatment will consist of transplantation (via self-administration) of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material four times daily in both eyes for a three month interval.

    Other: Corneal Epithelial Stem Cell Transplant

Interventions

  • OtherCorneal Epithelial Stem Cell Transplant

    Self-administration of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material.

05

What researchers measure

Primary outcomes

  1. Ocular Surface Disease Index (OSDI)

    Patient Reported Outcome by Survey

    Time frame: 3 months

Secondary outcomes

  1. Visual Acuity

    Snellen

    Time frame: 3 months

  2. Corneal Topography

    Automated corneal topographic indices

    Time frame: 3 months

06

Study locations

1 site
  • Rush Eye Associates
    Amarillo, Texas 79109, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03302273
Lead sponsor
Sloan W. Rush, MD
Responsible party
Sloan W. Rush, MD (Physician, Panhandle Eye Group, LLP) — Sponsor-investigator
First posted
Oct 5, 2017
Start date
Feb 1, 2019
Primary completion
Apr 1, 2022
Completion
Apr 1, 2022
Last update
Apr 21, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion